Introduction:
The biosimilar market in China is experiencing rapid growth, driven by factors such as increasing healthcare expenditure, a growing aging population, and government initiatives to promote the use of biosimilars. According to industry reports, the global biosimilar market is projected to reach $35 billion by 2026, with China emerging as a key player in the industry.
Spotlight Top 50 Major Biosimilar Producers in China 2026:
1. Shanghai Henlius Biotech Inc.
Shanghai Henlius Biotech Inc. is one of the leading biosimilar producers in China, with a market share of 15% in the country. The company specializes in the development and commercialization of biosimilar products for oncology and autoimmune diseases.
2. Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd. is another major player in the Chinese biosimilar market, with a production volume of over 10,000 units per year. The company has a strong presence in the domestic market and is expanding its reach internationally.
3. Bio-Thera Solutions Ltd.
Bio-Thera Solutions Ltd. is a biopharmaceutical company that focuses on the development of innovative biosimilars. The company has seen significant growth in recent years, with a 20% increase in exports in 2025 alone.
4. Innovent Biologics, Inc.
Innovent Biologics, Inc. is a leading biopharmaceutical company in China, with a focus on the development and commercialization of biosimilar products. The company has a market share of 12% in the country and is expected to expand its presence in the global market.
5. Fosun Pharma
Fosun Pharma is a major player in the Chinese biosimilar market, with a production volume of over 15,000 units per year. The company has a diverse portfolio of biosimilar products and has been expanding its presence in international markets.
Insights:
The biosimilar market in China is poised for significant growth in the coming years, driven by factors such as increasing demand for affordable healthcare solutions, government support for the industry, and technological advancements in biopharmaceuticals. According to industry forecasts, the Chinese biosimilar market is expected to grow at a CAGR of 25% from 2021 to 2026, reaching a market size of $5 billion by the end of the forecast period. As Chinese companies continue to invest in research and development and expand their global reach, they are likely to play a key role in shaping the future of the biosimilar industry.
Related Analysis: View Previous Industry Report
